Loading AI tools
This is an archive of past discussions about Chronic obstructive pulmonary disease. Do not edit the contents of this page. If you wish to start a new discussion or revive an old one, please do so on the current talk page. |
Archive 1 | Archive 2 |
Why is there no mention of this? [1]
People appear to be receiving the treatment successfully in the UK already: http://www.watfordobserver.co.uk/news/14664556.Woman_first_in_the_country_to_have_new_treatment_for_lung_disease/
Hello fellow Wikipedians,
I have just modified one external link on Chronic obstructive pulmonary disease. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
When you have finished reviewing my changes, please set the checked parameter below to true or failed to let others know (documentation at {{Sourcecheck}}
).
This message was posted before February 2018. After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than regular verification using the archive tool instructions below. Editors have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the RfC before doing mass systematic removals. This message is updated dynamically through the template {{source check}}
(last update: 5 June 2024).
Cheers.—InternetArchiveBot (Report bug) 07:24, 24 November 2016 (UTC)
The following Wikipedia contributor may be personally or professionally connected to the subject of this article. Relevant policies and guidelines may include conflict of interest, autobiography, and neutral point of view.
|
My edit request is in reference to the paragraph below:
...Treatment with stem cells is under study.[160] While there is tentative data that it is safe and with promising animal data there is little human data as of 2014.[161][162][163] Some of the human data that is available has found poor results.[164]
After reviewing the cited articles within the paragraph above, the sentence, "Some of the human data that is available has found poor results"--albeit true--seems particularly pointed and unindicative of the full state of research within the field. After reviewing the same source articles listed in the paragraph above (although a few are now greater than 3 years old) I believe this paragraph below is a more balanced and accurate summary of the state of stem cell therapy research and it's efficacy for the treatment of lung disease.
Suggested Edit:
"In recent years, treatment using stem cells has undergone a gradual shift from animal to human studies. [160] Although animal studies have shown promising results--proving efficacy in repopulating airway and alveolar epithelial cell lineages during homeostasis and repair--more clinical testing in humans is necessary in order to better understand the reparative mechanisms currently exhibited in rats. [161][162][163] Though treatment effectiveness in humans can vary, stem cell therapy and its ability to reduce systemic inflammation and reprogram developmental pathways to induce lung regeneration may be proven a risky but promising pathway.[164]"
I believe this is a fairer and more accurate depiction of stem cell therapy using the original sources of the initial paragraph, while the suggested changes have originated directly from its listed sources. --Ckennerly (talk) 17:41, 18 January 2017 (UTC)
This edit request to Chronic obstructive pulmonary disease has been answered. Set the |answered= or |ans= parameter to no to reactivate your request. |
Suggested Edit:
"In recent years, treatment using stem cells has undergone a gradual shift from animal to human studies. [160] Although animal studies have shown promising results--proving efficacy in repopulating airway and alveolar epithelial cell lineages during homeostasis and repair--more clinical testing in humans is necessary to better understand the reparative mechanisms currently exhibited in rats. [161][162][163] Though treatment effectiveness in humans can vary, stem cell therapy and its ability to reduce systemic inflammation and reprogram developmental pathways to induce lung regeneration may be proven a risky but promising pathway.[164]" Ckennerly (talk) 19:09, 23 February 2017 (UTC)
Ckennerly, thank you for disclosing your COI and your identity, and for agreeing to abide by WP:NOPAY. That's very much appreciated. The problem is that the company you work for is selling something, so it may not be possible for you to write about it neutrally. On their website, even when their blog posts are about other issues (e.g. pursed-lip breathing, diet), they always conclude with a plug for stem-cell therapy.
Rather than suggest an edit, can you say what's wrong with the current version, in your view? It says:
Treatment with stem cells is under study.[1] While there is tentative data that it is safe and with promising animal data there is little human data as of 2014.[2][3][4] Some of the human data that is available has found poor results.[5]
{{cite journal}}
: CS1 maint: unflagged free DOI (link)SarahSV (talk) 01:21, 8 March 2017 (UTC)
Previous text (26 Nov 2015)
Treatment with stem cells is under study,[1] and while generally safe and with promising animal data there is little human data as of 2014.[2]
| |
Current text (9 March 2017)
Treatment with stem cells is under study.[1] While there is tentative data that it is safe, and the animal data is promising, there is little human data as of 2014.[2][3][4] Some of the human data has shown poor results.[5]
| |
Ckennerly proposal (7 March 2017)
In recent years, treatment using stem cells has undergone a gradual shift from animal to human studies.[1] Although animal studies have shown promising results--proving efficacy in repopulating airway and alveolar epithelial cell lineages during homeostasis and repair--more clinical testing in humans is necessary in order to better understand the reparative mechanisms currently exhibited in rats.[2][3][4] Though treatment effectiveness in humans can vary, stem cell therapy and its ability to reduce systemic inflammation and reprogram developmental pathways to induce lung regeneration may be proven a risky but promising pathway.[5]
|
Ckennerly, above are the three versions we're discussing. Please check the references in your version, as the final one was a 2002 paper, so I swapped it for the one you intended to add. You appear to have used the VisualEditor to make the edits, and that has caused problems with the references (it's in experimental mode; using "edit source" may be easier). This is the diff of your edit; as you can see, it slotted some numbers in, and those attached the wrong references.
Anyway, your main objection is to the final sentence of the current version: "Some of the human data has shown poor results," sourced to PMID 23256721. Do you have access to that source, and if so are you willing to forward it to me? SarahSV (talk) 19:03, 9 March 2017 (UTC)
The closing line is from the reference [164] and can be found at: http://www.eurekaselect.com/106217/article
[160] Chong, Jimmy; Leung, Bonnie; Poole, Phillippa (2013-11-04). "Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease". The Cochrane Database of Systematic Reviews (11): CD002309. doi:10.1002/14651858.CD002309.pub4. ISSN 1469-493X. PMID 24190161.
[161] Inamdar, AC; Inamdar, AA (October 2013). "Mesenchymal stem cell therapy in lung disorders: pathogenesis of lung diseases and mechanism of action of mesenchymal stem cell.". Experimental lung research. 39 (8): 315–27. doi:10.3109/01902148.2013.816803. PMID 23992090.
[162] Conese, M; Piro, D; Carbone, A; Castellani, S; Di Gioia, S (2014). "Hematopoietic and mesenchymal stem cells for the treatment of chronic respiratory diseases: role of plasticity and heterogeneity.". TheScientificWorldJournal. 2014: 859817. doi:10.1155/2014/859817. PMC 3916026Freely accessible. PMID 24563632.
[163] McQualter, JL; Anthony, D; Bozinovski, S; Prêle, CM; Laurent, GJ (November 2014). "Harnessing the potential of lung stem cells for regenerative medicine.". The international journal of biochemistry & cell biology. 56: 82–91. doi:10.1016/j.biocel.2014.10.012. PMID 25450456.
[164] Tzouvelekis, A; Ntolios, P; Bouros, D (2013). "Stem cell treatment for chronic lung diseases.". Respiration; international review of thoracic diseases. 85 (3): 179–92. doi:10.1159/000346525. PMID 23364286.
Does this make sense? --Ckennerly (talk) 20:52, 9 March 2017 (UTC)
Cameron, I've had a chance to look at Tzouvelekis, Laurent and Bouros (2013), the ref for your proposed final sentence:
Though treatment effectiveness in humans can vary, stem cell therapy and its ability to reduce systemic inflammation and reprogram developmental pathways to induce lung regeneration may be proven a risky but promising pathway.
That doesn't seem to be a fair summary of the paper's conclusion. The authors conclude (paragraph break added):
So far there is still an open question regarding applicability of stem cell therapy in COPD patients: “Is it a scientific reality or just an alternative scenario of Promytheus myth?" ... [The constant process of maintenance and regeneration of the human lung] leads to a complete renewal of all lung cells and protein pool every 100 days meaning that by the age of 75 years an otherwise healthy subject will have renewed approximately 300 lungs. Although the aforementioned number is arbitrary and is based mainly on animal data it is still considerably high and underlines the tremendous regenerative capacity of human lung that is severely hampered by age, smoking and chronic lung disorders such as COPD. Repairing and regenerating lung structure and function represents the great hype for the treatment of COPD. ...
Understanding the molecular mechanisms regulating mobilization and activation of resident progenitor cells is of critical importance to identify novel therapeutic targets. Reducing systemic inflammation and reprogramming developmental pathways to induce lung regeneration may be proven a risky but promising pathway (Fig. 1). Nevertheless, we should always keep in mind the potential side-effects of these stem cell based therapies since many of the current neoplastic diseases arise from stem cells. Therefore, it is crucial when you inform the patients regarding stem cell therapeutic applications to separate the hope from the hype. There is plenty of room for technical improvements, further development, and more widespread acceptance and accessibility. For these cell-based therapies to become truly evolutionary there is only one approach: large, multicentric, randomized safety and efficacy clinical trials.
Regarding its use to support the current sentence: "Some of the human data has shown poor results", the relevant passage is:
The first study was recently published by Ribeiro-Paes J et al. [54] who reported a marginal statistically significant improvement in functional parameters as well as in exercise capacity in patients with severe COPD after an intravenous administration of autologous bone marrow derived MSCs. However, this study was severely underpowered with only 3 eligible for analysis patients posing major limitations to the data presented. Regarding the second phase II clinical trial, sponsored by Osiris Pharmaceuticals, recruitment has been completed and a total of 62 patients, with diagnosis of moderate (n=23) or severe (n=39) COPD patients, based on the recent GOLD functional criteria [1], have been enrolled and are being followed for a period of two years in the placebo-controlled study. Despite the great hype that was generated, first anecdotal results are rather disappointing highlighting the need for careful study design before rigid conclusions can be drawn. Official findings and publication are greatly anticipated.
That was 2013. Has the Osiris Pharmaceuticals study been published? SarahSV (talk) 03:19, 14 March 2017 (UTC)
"Though treatment effectiveness in humans can vary, stem cell therapy and its ability to reduce systemic inflammation and reprogram developmental pathways to induce lung regeneration may be proven a risky but promising pathway"
--Is taken as a standalone sentence. However, I think the proposed edit more-or-less covers the general consensus that stem cell therapy for the treatment of lung disease still requires large and continuous studies to understand the efficacy it has exhibited in rat models. I believe the sentences above it accurately portray the field as one that has potential but is still a while away from being a definitive alternative. Do you think there's a middle ground in finding this sense of balance within my suggested edit and the current version?Ckennerly (talk) 03:22, 14 March 2017 (UTC)
What I see in that paper (PMID 28119741) is: "However, despite the advances made in recent decades, we are still far from our goals and there are substantial hurdles to be overcome." And:
In addition to the safety issue, the efficacy issue is another important hurdle that should be surpassed. In contrast to animal models that have shown promising results, all of the current clinical trials aimed at regenerating the damaged lung in human subjects, irrespective of the modality, have been unsuccessful in terms of efficacy29,30,31,32,33,34,35. Since the sources of these discrepancies between the laboratory and clinical results are unclear, it is crucial to assess the possible causes of the recent disappointing results in clinical fields and to identify the possible ways to surmount the barriers.
That reflects what our current article says: "While there is tentative data that it is safe, and the animal data is promising, there is little human data as of 2014.[162][163][164] Some of the human data has shown poor results."[165]
In fact, we should probably remove "some of" from that sentence. SarahSV (talk) 20:36, 14 March 2017 (UTC)
This article: http://www.jhltonline.org/article/S1053-2498(15)00708-1/abstract
Ckennerly (talk) 03:01, 15 March 2017 (UTC)
I'd also like to propose a final edit to the current text as its brevity seems to belie the full state of the field.
Current text:
Proposed text:
doi:10.1016/S0140-6736(17)31222-9 JFW | T@lk 20:50, 14 May 2017 (UTC)
Is there a reason why pulmonary emphysema redirects here? My personal opinion is that it warrants its own page, as this just doesn't offer enough space to go into detail. — Preceding unsigned comment added by Decthost (talk • contribs) 07:24, 4 May 2017 (UTC)
Many previous definitions of COPD have emphasized the terms “emphysema” and “chronic bronchitis”, which are not included in the definition used in this or earlier GOLD reports. Emphysema, or destruction of the gas-exchanging surfaces of the lung (alveoli), is a pathological term that is often (but incorrectly) used clinically and describes only one of several structural abnormalities present in patients with COPD.
Chronic bronchitis, or the presence of cough and sputum production for at least 3 months in each of two consecutive years, remains a clinically and epidemiologically useful term, but is present in only a minority of subjects when this definition is used. However, when alternative definitions are used to define chronic bronchitis, or older populations with greater levels of smoke or occupational inhalant exposure are queried, the prevalence of chronic bronchitis is greater.
Doc James, you changed "persistent respiratory symptoms and long-term poor airflow" to "long-term breathing problems due to poor airflow". Respiratory symptoms can be present without abnormal spirometry, and (if I've understand the sources correctly) there can be poor airflow without respiratory symptoms.
Also, you restored "Eventually everyday, such as walking up stairs, activities become difficult." I removed the stairs example, because stairs are often an early sign that there's a problem, not something that happens eventually. It's better as "Eventually everyday activities become difficult" without specifying. SarahSV (talk) 21:40, 27 September 2017 (UTC)
I'm thinking of slowly going through this and updating from GOLD 2013 to GOLD 2017. The current format uses the long citation in the text and repeats it for chapter 1, chapter 2, etc, giving the page ranges of the chapters. Would anyone mind if I moved the long ref to the end (under "Works cited" or similar), then added short cites (GOLD 2017) with page numbers using {{sfn}}? This would mean we not only avoid repeating the long citation, but we could also add page numbers instead of ranges. SarahSV (talk) 00:09, 27 September 2017 (UTC)
Okay, no response, so I will start converting to refname=GOLD2017, with {{rp}} for page numbers. This will avoid the long citation being repeated for chapters, but it will mean (a) the ref name (eventually) being repeated a lot, and (b) the ugly numbers after the refs. SarahSV (talk) 20:58, 28 September 2017 (UTC)
I've done a few, but it's ugly. The report will be cited a lot, and {{rp}} will be repeated throughout the text, especially given the desire to repeat refs after every sentence. Are you sure you prefer that to GOLD 2017, 6, using {{sfn}}? Pinging Doc James. Here's an example of the latter. It's neat, there are no long cites to repeat, you've got precise page numbers rather than chapters, no mess in the text with {{rp}}, and the link takes you to the report at the end. SarahSV (talk) 03:40, 29 September 2017 (UTC)
Okay, understood. The length of the report (123 pages) means we should treat it as a book. So to summarize (if I've understood correctly):
Doc James, are you willing to allow sfn if we keep it out of the lead?
Jytdog, are you willing to allow sfn for reports and books used more than once, if the long cite is kept in the text rather than at the end? And with no short cites in the lead. (Note: the only report is GOLD 2017, because it will replace GOLD 2013 and GOLD 2007.)
See Parkinson's disease for an example of what I'd like to do, where short cite 90, with page numbers, points to long cite 35. But journal articles are long cites only.
In the meantime, to make progress, I will start adding GOLD 2017 with chapters, and page numbers commented out to help editors (but note that this doesn't help readers). Then we can take our time to choose the best system. SarahSV (talk) 17:05, 29 September 2017 (UTC)
Doc James, can you explain the revert? I changed: "When compared to tiotropium, the LAMAs including aclidinium, glycopyrronium, and umeclidinium, appear to have a similar level of effectiveness" to "A 2015 network meta-analysis indicated that aclidinium, glycopyrronium, tiotropium, and umeclidinium were more effective than placebo." And added a quote from the source to support it. SarahSV (talk) 03:10, 9 March 2018 (UTC)
"Traditionally two common types of COPD were known as chronic bronchitis and emphysema"
https://books.google.com/books?id=li1VCwAAQBAJ&pg=PA913
WHO says "The more familiar terms “chronic bronchitis” and “emphysema” have often been used as labels for the condition."
User:Mikael Häggström the definition you added was an older one?
Doc James (talk · contribs · email) 00:29, 24 March 2018 (UTC)
Are the sources for the two Knowledge Diffusion videos available anywhere? File:Chronic bronchitis.webm and File:Emphysema.webm. SarahSV (talk) 15:53, 28 March 2018 (UTC)
I found an article called the "Dutch hypothesis" in the list of orphaned articles. According to its last paragraph, it's one of the four main hypothesis for the pathogenesis of COPD. I find that strange, since it's not listed in here at all, despite this being considered a GA-class article. I'm no medical professional, so I don't know the proper way to incorporate it into the article, especially since there's no section comparing COPD hypothesis by name. — Preceding unsigned comment added by Matthew V. Milone (talk • contribs) 20:52, 24 July 2018 (UTC)
There is a mix of styling for just one reference the GOLD 2013 report, resulting in a dead link for several of these. One is cited as a book giving chapters and page numbers (dead link ref) it is not usual for a journal to be broken up into chapters and page numbers they are easy enough to scroll through and item-searchable. I shall list them as the one searchable ref.--Iztwoz (talk) 08:40, 4 May 2019 (UTC)
References
The distinction is 1) the terms chronic bronchitis and emphysema are no recommended officially for COPD 2) chronic bronchitis is a clinical symptoms 3) emphysema is a pathological finding.
"It is unclear whether different types of COPD exist.[1] While previously divided into emphysema and chronic bronchitis, emphysema is only a description of lung changes rather than a disease itself, and chronic bronchitis is simply a descriptor of symptoms that may or may not occur with COPD.[2]"
GOLD is a way better source than either ADAM or the NHS for this. We need discussion before changing User:Iztwoz.
Doc James (talk · contribs · email) 17:50, 30 April 2019 (UTC)
Text is still in the 2019 edition of the GOLD report. Will update.
Basically Chronic bronchitis is used in two different ways. 1) it is used to mean COPD and is the most common usage 2) it is used to mean a productive cough that lasts more than three month in each of two years.
Chronic bronchitis is technically not a condition but a symptom. Doc James (talk · contribs · email) 06:16, 1 May 2019 (UTC)
User:Iztwoz Which ref says this is "Bronchiolitis obliterans" or "obliterative bronchiolitis"? Doc James (talk · contribs · email) 05:45, 20 May 2019 (UTC).
And as much as it is your personal opinion that these conditions are not diseases - countless refs assert that they (both chronic bronchitis and emphysema) are - yet you remove their inclusion. ? This is hardly NPOV.--Iztwoz (talk) 13:05, 22 May 2019 (UTC)
User:Doc James Where does it state that Chronic bronchitis and Emphysema are older terms for the condition.? As earlier attempts have been made to reword this and been reverted - once by myself and previously by another - (Mikael Haagstrom) I'll try again here. As suggested to you earlier the use of the word "older" implies that the conditions separately do not exist, which is patently not true. It would seem that you have tried to render these conditions as obsolete by making redirects to this page. One ref given uses the following - "Traditionally two common types of COPD were known as chronic bronchitis and emphysema..." The WHO ref says that "the more familiar terms chronic bronchitis and emphysema have been used as labels for the condition". These just point to the "newness" of the use of the term COPD and that it now covers both chronic bronchitis and emphysema. Seems like a lot of cherry-picking has been going on to support a POV or given take on a subject. For example Asthma has not been included yet the same WHO ref states that some cases of COPD are due to long term asthma. A search on WHO site for emphysema lists many refs to "COPD, such as chronic bronchitis or emphysema..." that clearly is not saying that these are older terms for the condition. Also not all countries are agreed on what to include and this fact is not to be found on the page, solely that accepted by the US. The condition of emphysema seems to have been airbrushed away - the page pneumatosis on searches seems to relate to gastric emphysema. Do you have any objections to a new page of Pulmonary emphysema being created?--Iztwoz (talk) 14:19, 20 May 2019 (UTC)
We could have an article called "Pathophysiology of COPD" were we could discuss the pathophysiological details of "emphysema" at greater length (if anyone is interested in doing so). The problem with creating an article on "Pulmonary emphysema" is that it may simple get filled full of content duplicating COPD with efforts to present it as a disease in and of itself rather than simple a pathological finding. Doc James (talk · contribs · email) 08:48, 21 May 2019 (UTC)
Guys, I just checked back in on the lead of this article and it is much improved (when I drop in on an article like this, it is often because it's thrown a red flag that I patrol for, and thus is generally in a bit of a mess). "Chronic bronchitis and emphysema are older terms used for different types of COPD". I would say that they are older terms for the two primary symptoms of COPD, Chronic obstructive pulmonary disease § Cough and Chronic obstructive pulmonary disease § Shortness of breath. "Cough" (chronic bronchitis) is what keeps the tobacco victim in the bathroom so long, with their endless hacking and spitting into the sink. "Shortness of breath" (emphysema) is what keeps them tethered to their oxygen machine or mobile tanks. I'd guess that the vast majority (over 90%) of (advanced) COPD patients experience both symptoms, and that's why the two older "separate" diseases were lumped together in order to give them a single disease called COPD. If I'm right, then maybe you could update the article to say so. Or say whatever the percentage is, it's probably not exactly 90%. Actually, the lead of the "Signs and symptoms" section summarizes that in a way that makes sense to me. – wbm1058 (talk) 10:23, 5 June 2019 (UTC)
Just a few notes on the GA review request made: The GA was given in 2013. In 2019 the page has almost doubled with no further review. Also i think the size of the page has increased needlessly due to the 'merging' of emphysema - an important page in its own right that has now disappeared. A search for emphysema redirects here. Likewise think the redirection of Chronic bronchitis to here completely unnecessary as it has its own home on the Bronchitis page and find constant references to it being just a cough confusing and unnecessary - many other conditions or diseases could be equally short changed for example a runny nose could do away with the condition of rhiinitis - ? It has since been made into a disambiguation page after i changed the redirect to Bronchitis section? this dab page is a nonsense as the topics are the same. was hoping that another review would look at these issues. And the confusing use of that sentence being older terms, (making those previous terms redirects here) which was already tried to be addressed has not been. Talk on the pages here and on Bronchitis do not seem to make much headway. --Iztwoz (talk) 14:52, 5 June 2019 (UTC)
As brought up before - the umbrella term definition has changed in accord with the GOLD document. Also as brought up before the differences in defining COPD have not been addressed, when i added something from the ALA you reverted saying that the ALA was a charity yet it is used in the GOLD report - the first ref in fact. Can i ask you now - is the ALA an acceptable source? And is Medscape an acceptable source? --Iztwoz (talk) 17:28, 7 June 2019 (UTC)
Strangely the page can no longer be found - from 30 minutes ago.--Iztwoz (talk) 16:42, 14 June 2019 (UTC) https://www.who.int/en/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
In section that i had placed cn's in yesterday you removed these and used the same ref - can you please point out exactly where these items are - the archived link is a dead link - the other link goes to a page that is unsearchable PMID 22878278. This link gives a searchable document and i can find no ref at all to these included items. --Iztwoz (talk) 07:36, 10 June 2019 (UTC)
What am i supposed to be looking at in Chapter 5 page 45?- can see nothing of any relevance and even if i did it is not related to Chapter 2 which is the reference used for the section 'Cough'.--Iztwoz (talk) 07:38, 15 June 2019 (UTC) Sorry-had already noted the difference.--Iztwoz (talk) 14:21, 15 June 2019 (UTC)
Thank you for the links - the summary had looked like the whole report. Have now seen some of the queried info on the report - but i did not see ref to common colds. Also the whole section could do with a bit of re-write, the 'sputum produced can change over hours to days' does not to me equate with what the source says or inform anything, and the sentence relating to sputum 'being spat out or swallowed needs to include the difficulty of evaluating its production (if the sentence is to be included at all. Might be better as source has done, in making a bit of separation of cough and sputum, as the important note that the cough in COPD is not always productive is somehow 'lost' in section. and there is still the deadlink to the archived copy.--Iztwoz (talk) 07:22, 15 June 2019 (UTC)
I am unclear what you are pushing for:
1) Do you agree that chronic bronchitis and emphysema were once terms for types of COPD? Doc James (talk · contribs · email) 03:22, 16 June 2019 (UTC)
2) Do you agree that these terms are no longer recognized as types of COPD? Doc James (talk · contribs · email) 03:22, 16 June 2019 (UTC)
3) Do you agree that chronic bronchitis remains a symptom defined condition? Doc James (talk · contribs · email) 03:22, 16 June 2019 (UTC)
4) Do you agree that emphysema remains a pathological change? Doc James (talk · contribs · email) 00:44, 10 June 2019 (UTC)
Doc James (talk · contribs) In the link to the Ferri's ebook you gave on this page, it states the following:
"Traditionally COPD was described as encompassing emphysema, characterised by loss of lung elasticity and destruction of lung parenchyma with enlargement of air spaces, and chronic bronchitis, characterised by obstruction of small airways and productive cough - 3 months for more than 2 successive years. These terms are no longer included in the definition of COPD, although they are still used clinically.” (page 299)
This is an updated newer version that reflects the GOLD position, and is a very clearly written paragraph. All the confusion has arisen from the mismatch of older and newer information on the page. If this newer reading is instead incorporated into the lead thus changing the version that refers to 'older terms' all else could follow through, including the reinstatement of the clinical use of chronic bronchitis and emphysema. I really do hope that you can appreciate the difference this would make.--Iztwoz (talk) 19:11, 5 June 2019 (UTC)
You appear to refuse to accept what the World Health Organization has written which is:
"Chronic Obstructive Pulmonary Disease (COPD) is not one single disease but an umbrella term used to describe chronic lung diseases that cause limitations in lung airflow. The more familiar terms 'chronic bronchitis' and 'emphysema' are no longer used, but are now included within the COPD diagnosis."
https://www.who.int/respiratory/copd/en/
https://www.who.int/en/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd) --Iztwoz (talk) 15:15, 15 June 2019 (UTC)
I am not sure why? WHO is an excellent source. Yes it is confusing. The same term can be used in different ways. One does not need to try to force consistently into the language. This same problem exists in a number of medical topics. Doc James (talk · contribs · email) 20:23, 5 June 2019 (UTC)
In MEDRS - a section headed Medical and scientific organisations states that info from the National Academy of Sciences is acceptable - so how is the journal of the NAS the PNAS not acceptable and said to be a primary source? What am I missing here? --Iztwoz (talk) 19:31, 7 July 2019 (UTC)
I'm new to Wikipedia so please forgive any neophyte errors. The Management section does not currently have a section discussing Airway clearance techniques (ACTs) for COPD. I wanted to suggest an addition of a subheading along the lines of: "Airway clearance techniques (ACTs) aim to address cough and sputum production by removing sputum from the lungs. ACTs such as 'conventional' therapy (e.g. postural drainage, percussion, vibration), autogenic drainage, hand-held positive expiratory pressure (PEP) devices, and mechanical devices applied to the chest wall attempt to clear mucus from the lungs. In people with acute COPD, ACTs may reduce the need for increased ventilatory assistance and the duration of ventilatory assistance, and length of hospital stay. In people with stable COPD, ACTs may lead to short-term improvements in health-related quality of life and a reduced long-term need for hospitalisations related to respiratory issues." Citation: Osadnik, C. R., McDonald, C. F., Jones, A. P., & Holland, A. E. (2012). Airway clearance techniques for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews, (3). https://www.ncbi.nlm.nih.gov/pubmed/22419331?dopt=Abstract Would welcome any thoughts or comments. Thank you! --Audrey.r.tan (talk) 12:17, 6 September 2019 (UTC)
The following article is given as a reference to the statement on this Wikipedia page that "In contrast to asthma, the airflow reduction does not improve much with the use of a bronchodilator.[3]".
However, the article (currently) doesn't say anything about the effects of a bronchodilator.
Should the terms "chronic bronchitis" and "emphysema" redirect here or elsewhere? Doc James (talk · contribs · email) 22:32, 23 September 2019 (UTC)
User:Iztwoz Were you going to make a proposal that people can support? Doc James (talk · contribs · email) 02:41, 25 September 2019 (UTC)
"Chronic bronchitis" and "emphysema" are old names for COPD and we need to make sure this remains clear. Doc James (talk · contribs · email) 23:49, 27 September 2019 (UTC)
i think this is a specific condition associated with COPD that i didnt see mentioned. its an increase of CO2 in the blood, like with divers, and is itself deadly. i may add, but would appreciate someone else noticing this and adding it. 69.216.101.196 (talk) 16:56, 20 April 2021 (UTC)
The section on Management states that "Stopping smoking decreases the risk of death by 18%." Sadly, the risk of death is 100% for all of us. Perhaps it should say "the risk of death from COPD" or "the risk of death in a given year" or something. Aymatth2 (talk) 16:18, 10 November 2019 (UTC)
Colin is it better to just include page numbers for latest Gold report, as it seems that a different format is needed for each chapter.? --Iztwoz (talk) 17:39, 28 June 2021 (UTC)
Hi, I can't see this in the citation "The disease affects men and women almost equally, as there has been increased tobacco use among women in the developed world.[185]". Am I losing the plot? Graham Beards (talk) 11:46, 29 June 2021 (UTC)
Seamless Wikipedia browsing. On steroids.
Every time you click a link to Wikipedia, Wiktionary or Wikiquote in your browser's search results, it will show the modern Wikiwand interface.
Wikiwand extension is a five stars, simple, with minimum permission required to keep your browsing private, safe and transparent.